摘要
目的:观察依达拉奉对急性重型颅脑损伤患者血清神经元特异性烯醇化酶(NSE)和S-100β蛋白的影响及临床疗效。方法:将72例急性重型颅脑损伤患者随机分为治疗组和对照组,每组36例。两组均给予常规治疗,治疗组在此基础上加用依达拉奉注射液治疗,连用14 d。于治疗前、治疗后4 d和7d检测两组患者血清NSE和S-100β水平,并观察两组格拉斯哥昏迷评分(GCS)的变化及伤后3个月格拉斯哥预后分级评分(GOS)情况。结果:两组治疗14 d后的GCS评分比较,差异有显著性意义(P<0.001),治疗组优于对照组。治疗组在治疗3个月后的恢复良好率(55.5%)显著高于对照组(27.8%)(P<0.05)。在治疗后4d和7d,治疗组血清NSE和S-100β水平均较对照组显著降低(P<0.001)。且未见明显不良反应。结论:依达拉奉可降低急性重型颅脑损伤患者血清NSE和S-100β水平,改善患者预后。
Objective： To observe the effect of edaravone on serum level of neuron specific enolase（NSE） and S-100β protein（S-100β） in patients with acute severe brain injury.Methods： Seventy-two patients with acute severe brain injury were randomly divided into treatment group（36 cases） and control group（36 cases）,two groups were both given with conventional treatment,while the treatment group was also given with extra injection of edaravone for 14 d.Serum NSE and S-100β were measured before and 1,4,7 days after the treatment respectively.Besides,changes of Glasgow coma scale（GCS） score and Glasgow Outcome Scale（GOS） 3 months after the injury were observed and compared between the 2 groups.Results： The GCS score of the treatment group was significantly higher than that of the treatment group 14 days after the treatment（P〈0.001）.3 months after injury,good outcomes were shown in 55.5% patients of the treatment group,significant higher than the 27.8% of the control group（P〈0.05）.The decrease of serum levels of NSE and S-100β in treatment group was significant higher than that of the control after 4 d or 7 days of treatment（P〈0.001）.Conclusion： Edaravone can reduce the serum levels of NSE and S-100β in patients with acute severe brain injury and improve the prognosis.
出处
《海南医学院学报》
CAS
2010年第5期552-554,共3页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(00201000145)~~
